Taft attorney Stephen Auten will present at the 7th Annual Biosimilars Long View Conference on Dec. 2 in New York. The conference will focus on regulatory and commercialization aspects of biosimilars and is hosted by Dr. Ronny Gal, one of the top industry analysts. Auten’s presentation is titled “Investors’ Legal Guide to U.S. Biosimilars.”
Auten is head of Taft's Pharmaceutical and Life Sciences Litigation practice area. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDA Litigation Forum," which has more than 5,500 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.